vTv Therapeutics
Yahoo Finance • last year
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatme... Full story
Yahoo Finance • last year
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatme... Full story
Yahoo Finance • last year
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatme... Full story
Yahoo Finance • last year
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin(TTP399) as an adjunctive therapy to insulin for the treatmen... Full story
Yahoo Finance • last year
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatm... Full story
Yahoo Finance • 2 years ago
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
HIGH POINT, N.C., June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatme... Full story
Yahoo Finance • 2 years ago
CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
WESTON, Fla., June 15, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatme... Full story
Yahoo Finance • 2 years ago
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetes Biotech industry and Wall Street veteran Steven Tuch appointed Executive Vice President and Chief Finan... Full story
Yahoo Finance • 2 years ago
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced... Full story
Yahoo Finance • 2 years ago
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for t... Full story
Yahoo Finance • 2 years ago
vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and member of the Board of Directors Agreements with CinRx P... Full story
Yahoo Finance • 2 years ago
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
Paul Sekhri appointed as President, Chief Executive Officer and Board member. Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to leverage CinRx’s industry experience to collaborate in overse... Full story
Yahoo Finance • 2 years ago
Months after celebrating its first exit, CinRx invests $10M in newest portfolio company
A Cincinnati-based portfolio company that celebrated a massive exit earlier this year has invested millions to accelerate development of a new treatment option for people with Type 1 diabetes.... Full story
Yahoo Finance • 3 years ago
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced... Full story
Yahoo Finance • 3 years ago
vTv Therapeutics Announces Investment by CinRx Pharma
vTv Therapeutics Inc. HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a subsidiary of CinRx Ph... Full story
Yahoo Finance • 3 years ago
vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
HIGH POINT, N.C., June 04, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced... Full story
Yahoo Finance • 3 years ago
Aravive Appoints Rudy Howard as Chief Financial Officer
HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Rudy Howard a... Full story
Yahoo Finance • 3 years ago
vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare
HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (“G42 Investments”). Under the ter... Full story
Yahoo Finance • 3 years ago
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the progress of its clinical programs. Recent... Full story
